ESTRO 2020 Abstract Book

Multimodal approach to oligometastatic breast disease: current state-of-the-art..................................... (Abs. 260-262) The role of radiotherapy in locally advanced pancreatic cancer................................................................... (Abs. 263-266) How to enhance the quality of treatment planning studies.......................................................................... (Abs. 267-269) Application of machine learning to CTV definition.......................................................................................... (Abs. 270-272) Patient involvement in radiation oncology...................................................................................................... (Abs. 273-275) Poster Highlights Poster highlights 9 CL: Lung.............................................................................................................................. (Abs. 276-282) Poster highlights 10 PH: Toxicity modelling..................................................................................................... (Abs. 283-289) Poster discussion CL: Breast 2......................................................................................................................................................... (Abs. 290-295) PH: Quantitative functional and biological imaging........................................................................................ (Abs. 296-300) PH: Treatment planning: applications 2........................................................................................................... (Abs. 301-306) PH: Adaptive radiotherapy and inter-fraction motion management 1......................................................... (Abs. 307-312) Proffered Papers Proffered papers 14: QoL and PROMs............................................................................................................. (Abs. 313-318) Proffered papers 15: Radiation response biomarkers................................................................................... (Abs. 319-324) Proffered papers 16: Breast.............................................................................................................................. (Abs. 325-330) Proffered papers 17: GI. .................................................................................................................................... (Abs. 331-336) Proffered papers 18: Intra-fractional motion management.......................................................................... (Abs. 337-342) Proffered papers 19: Auto-contouring using deep learning.......................................................................... (Abs. 343-348) Proffered papers 20: Ensuring precision and accuracy in RT........................................................................ (Abs. 349-354) Poster Highlights Poster highlights 11 CL : CNS............................................................................................................................ (Abs. 355-361) Poster highlights 12: PH Daily challenges in routine RT................................................................................. (Abs. 362-368) Plenary Session Clinical trials........................................................................................................................................................ (Abs. 369-374) Joint Symposium ESTRO-EORTC: Redefining oligometastatic disease: incorporating advanced imaging into clinical trials................................................................................................................................................. (Abs. 375-378) Symposium Use of 3-dimensional organoid models in radiation research...................................................................... (Abs. 379-381) Controversies in locally advanced breast cancer............................................................................................ (Abs. 382-385) Second malignancy after modern radiotherapy: more or less than historical precedents........................ (Abs. 386-389) Radiobiological guidance for treatment planning........................................................................................... (Abs. 390-392) Audits for advanced radiotherapy techniques................................................................................................ (Abs. 393-396) Meet the Expert Meet-the-Expert -RTT led MR............................................................................................................................ (Abs. 397-398) Poster Highlights Poster highlights 13 CL : Gynaecology. ............................................................................................................ (Abs. 399-405) Poster highlights 14 PH: MRI only planning..................................................................................................... (Abs. 406-412) Poster discussion CL: Lung............................................................................................................................................................... (Abs. 413-418) CL: Upper and Lower GI 1.................................................................................................................................. (Abs. 419-424) PH: Radiobiological and predictive modelling, and radiomics 1.................................................................... (Abs. 425-430) PH: Implementation of new techniques 1. ...................................................................................................... (Abs. 431-436) Plenary Session Highlights of Proffered papers.......................................................................................................................... (Abs. 437-439) Proffered Papers Proffered papers 21: Protons............................................................................................................................ (Abs. 440-445) Proffered papers 22: Radiobiological resistance mechanisms...................................................................... (Abs. 446-451) Proffered papers 23 : Palliation........................................................................................................................ (Abs. 452-457) Proffered papers 24 : Lymphoma..................................................................................................................... (Abs. 458-463) Proffered papers 25 - Clinical implementation of online MRgRT.................................................................. (Abs. 464-469) Proffered papers 26: New technology.............................................................................................................. (Abs. 470-475)